We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
216 result(s) found, displaying 11 to 20
-
Cancellation by sponsorRequested by CSL Behring (Australia) Pty Ltd
-
Cancellation by sponsorRequested by CSL Behring (Australia) Pty Ltd
-
Australian public assessment report (AusPar)Andembry was approved for the prevention of recurrent hereditary angioedema (HAE) attacks in patients aged 12 years and older with C1-INH HAE (C1-esterase inhibitor deficiency or dysfunction).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for HIZENTRA human normal immunoglobulin 20% solution for subcutaneous injection 50 mL pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ANDEMBRY garadacimab 200 mg solution for injection in pre-filled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ANDEMBRY garadacimab 200 mg solution for injection in pre-filled syringe with needle safety device.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL US AlbuRx 5 human albumin 50 g/L (5% w/v) solution for intravenous infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL Hong Kong Albumex 5 NexGen Human Albumin 50 g/L Solution for Intravenous Infusion.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL United States of America Privigen normal immunoglobulin (human) (100g/L, 10%) solution for intravenous solution.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL New Zealand Fibrogammin Factor XIII, Freeze-Dried 1250 IU, powder forinjection vial with 20 mL diluent ampoule.